Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report

MLA

Haoran Bai, et al. “Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report.” OncoTargets and Therapy, vol. 14, July 2021, pp. 3983–89. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f64da4ae647d8ac03dc194429256b68c&authtype=sso&custid=ns315887.

APA

Haoran Bai, Xiaoqiang Gu, Dan Meng, Jinzu Yang, Jiahua Xu, Jianxin Qian, Ling Chen, Xin Li, & Hongwei Li. (2021). Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report. OncoTargets and Therapy, 14, 3983–3989.

Chicago

Haoran Bai, Xiaoqiang Gu, Dan Meng, Jinzu Yang, Jiahua Xu, Jianxin Qian, Ling Chen, Xin Li, and Hongwei Li. 2021. “Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report.” OncoTargets and Therapy 14 (July): 3983–89. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f64da4ae647d8ac03dc194429256b68c&authtype=sso&custid=ns315887.